Hopp til innhold
NHI.no
Annonse

Demens, legemidler: Galantamin (Galantamin, Reminyl)

Innhold i artikkelen

Galantamin finnes som depotkapsler på 8 mg, 16 mg eller 24 mg. Kapselen tas en gang daglig om morgenen. Anbefalt startdose er 8 mg daglig i minimum fire uker. Deretter økning til 16 mg dersom bivirkningene ikke er plagsomme. 16 mg er den dosen som regnes som nødvendig for å få full effekt av dette medikamentet.

Annonse

Eventuelt kan dosen økes til 24 mg daglig etter fire uker. Igjen er det mage-tarm bivirkninger som er hyppigst. Symptomer som påvirker psyken, vekt, væskebalansen, nervesystemet, ernæring, lever, hjerte eller hud kan forekomme. Dersom man mener å ha positiv effekt, men opplever mye bivirkninger, gjelder for alle preparatene at man kan trappe ned dosen ett nivå for å redusere bivirkninger.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Demens ved Alzheimers sykdom . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Demens. Nasjonal faglig retningslinje. Først publisert 16.08.2017. Sist faglig oppdatert 23.02.2024. www.helsedirektoratet.no
  2. McKhann GM, Knopman DS, Chertkow H, et al.. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263-9. pmid:21514250 PubMed
  3. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012 Jan;8(1):1-13. doi: 10.1016/j.jalz.2011.10.007. PMID: 22265587 PubMed
  4. Rongve A, Årsland D, Graff C. Alzheimers sykdom og genetikk. Tidsskr Nor Legeforen 2013; 133: 1449-52. doi:10.4045/tidsskr.12.0873 DOI
  5. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin. 1907. 64: 146-148.
  6. Gjøra L, Kjelvik G, Strand BH, et al. Forekomst av demens i Norge. Utgitt av Forlaget aldring og helse 2020. ISBN 978-82-8061-579-4 (PDF). butikk.aldringoghelse.no
  7. Seshadri, S, Beiser, A, Kelly-Hayes, M, Kase, CS, Au, R et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006; 37(2): 345-50. PMID: 16397184 PubMed
  8. Nasjonalt senter for aldring og helse. Demens. Fakta om demens. Siden lest 31.01.2023. www.aldringoghelse.no
  9. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. Lancet. 2016 Jul 30;388(10043):505-17. Epub 2016 Feb 24.pmid: 26921134 PubMed
  10. Small GW, Siddarth P, Ercoli LM, et al.. Healthy behavior and memory self-reports in young, middle-aged, and older adults. Int Psychogeriatr 2013; 25(6): 981-9. pmid:23425438 PubMed
  11. Hunskår S (red.). Allmennmedisin. S. 419. Gyldendal Norsk Forlag AS. Gyldendal Akademisk, 2003.
  12. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789. PMID: 33302541 PubMed
  13. Haass C, De Strooper B. Review: neurobiology - the presenilins in Alzheimer's disease - proteolysis holds the key. Science 1999; 286: 916-19. PubMed
  14. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009; 302: 2557-64. Journal of the American Medical Association
  15. Shea YF, Chu LW, Chan AO, et al.. A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Fomos Med Assoc 2016 Feb; 115(2): 67-75. pmid:26337232 PubMed
  16. Knapskog A-B, Engedal K, Selbæk G, Øksengård A-R. Alzheimers sykdom – diagnostikk og behandling. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.20.0919 DOI
  17. Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies. Curr Alzheimer Res. 2018;15(3):283-300. doi: 10.2174/1567205014666170417111859. PMID: 28413986. PubMed
  18. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132. PMID: 29850777; PMCID: PMC6022632.
  19. Strac DS, Muck-Seler D, Pivac N. Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review. Psychiatr Danub. 2015 Mar;27(1):14-24. PMID: 25751428 PubMed
  20. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2. PMID: 33667416 PubMed
  21. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease. Neurobiol Aging. 2017 Jan;49:214.e7-214.e11. doi: 10.1016/j.neurobiolaging.2016.07.018. Epub 2016 Aug 5. PMID: 27595457. PubMed
  22. Jones EL, Mok K, Hanney M, et al. Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiol Aging 2013; 34(10): 2441.e1-5. pmid:23601808 PubMed
  23. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug 10;404(10452):572-628. PMID: 39096926 PubMed
  24. Ferreira P, Ferreira AR, Barreto B, Fernandes L. Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews. Eur Geriatr Med. 2022 Feb;13(1):19-32. doi: 10.1007/s41999-021-00553-w. Epub 2021 Aug 17. PMID: 34403113 PubMed
  25. Hill NL, Mogle J. Alzheimer's disease risk factors as mediators of subjective memory impairment and objective memory decline: protocol for a construct-level replication analysis. BMC Geriatr 2018; 18(1): 260. pmid:30373526 PubMed
  26. Snowden JS, Thompson JC, Stopford CL, et al. The clinical dianosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; : doi: 10.1093/brain/awr189.
  27. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255–263. doi:10.1001/jamaneurol.2023.5319. PMID: 38252443 PubMed
  28. Lai R, Li B, Bishnoi R. P-tau217 as a Reliable Blood-Based Marker of Alzheimer's Disease. Biomedicines. 2024 Aug 13;12(8):1836. doi: 10.3390/biomedicines12081836. PMID: 39200300 PubMed
  29. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database of Systematic Reviews 2012; 9: CD009132. Cochrane (DOI)
  30. Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013; 185: 1393-401. pmid:24043661 PubMed
  31. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006; 1: CD005593. Cochrane (DOI)
  32. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-97. Annals of Internal Medicine
  33. Soysal P, Isik AT, Stubbs B, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016 Jun 3 . pmid:27261502 PubMed
  34. Lim AWY, Schneider L, Loy C Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2024; 11: CD001747. pub4. PMID: 39498781 PubMed
  35. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-92. PubMed
  36. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 957-9. New England Journal of Medicine
  37. Truong C, Recto C, Lafont C, et al. Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials. Neurology 2022. PMID: 36096687 PubMed
  38. Qizilbash N. Treatment of Alzheimer's disease. I: Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J et al. Evidence-based dementia practice. Oxford: Blackwell Science, 2002: 467 - 588.
  39. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 ;4:CD001191. PMID: 25858345. PubMed
  40. Engedal K, Brækhus A, Gjerstad L. Effekt av legemidler mot demens. Tidsskr Nor Lægeforen 2004; 124: 1641-2. PubMed
  41. Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord. 2014;37(1-2):71-85. doi: 10.1159/000353801 DOI
  42. Winblad B, Poritis N. Memantine in severe dementia: result of the 9M-best study. Int J Geriatr Psychiatry 1999; 14: 135 - 46. PubMed
  43. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub5. DOI
  44. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; e-pub.
  45. Lopez OL, Becker JT, Wahed AS. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7. PubMed
  46. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ 2012; 2: e000917. doi:10.1136/bmjopen-2012-000917 DOI
  47. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003120. DOI: 10.1002/14651858.CD003120.pub3. DOI
  48. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012. doi:10.1016/S1474-4422(12)70206-5 DOI
  49. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia. JAMA 2008; 300:2253-62. Journal of the American Medical Association
  50. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA 2009; 302: 2663-70. Journal of the American Medical Association
  51. Ruths S, Straand J. Antipsykotiske midler mot uro ved demens - medisinsk behandling eller kjemisk atferdsregulering?. Tidsskr Nor Lægeforen 2005; 125: 1672-5. PubMed
  52. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43. Journal of the American Medical Association
  53. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer`s disease. N Engl J Med. 2006; 355: 1525-38. PubMed
  54. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227. BMJ (DOI)
  55. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35. New England Journal of Medicine
  56. Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol 2016; 18(9): 40. pmid:27476067 PubMed
  57. Bentham P, Gray R, Sellwold E, et al. Aspirin in Alzheiemer's disease (AD 2000): a randomised open-label trial. Lancet Neurol 2008; 7: 41-9. PubMed
  58. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA 2008; 300: 1774-83. Journal of the American Medical Association
  59. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; 8: CD004514. Cochrane (DOI)
  60. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease. JAMA 2014; 311: 33-44. doi:10.1001/jama.2013.282834 DOI
  61. Farina N, Llewellyn D, Isaac MGEKN, et al. Vitamin E for Alzheimer`s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017; 4: CD002854. PMID: 28418065 PubMed
  62. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev 2016 11;4:CD009002 Cochrane (DOI)
  63. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD005379. DOI: 10.1002/14651858.CD005379.pub3 DOI
  64. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413 PubMed
  65. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023; 330: 512-527. pmid:37459141 PubMed
  66. Nicastro N, Assal F, Seeck M. From here to epilepsy: the risk of seizure in patients with Alzheimer's disease. Epileptic Disord 2016 Mar; 18(1): 1-12. pmid:26907471 PubMed
  67. Ljøstad U, Myglånd Å. Alzheimer demens. NEL Nevrologi. Sist oppdatert 24.10.2018. nevro.legehandboka.no
  68. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer's Dementia and Death: The Cache County Dementia Progression Study. Am J Psychiatry 2015. pmid:25585033 PubMed
  69. Murphy E, Froggatt K, Connolly S, O'Shea E, Sampson EL, Casey D, Devane D. Palliative care interventions in advanced dementia. Cochrane Database Syst Rev. 2016 Dec 2;12(12):CD011513. doi: 10.1002/14651858.CD011513.pub2. Update in: Cochrane Database Syst Rev. 2021 Sep 28;9:CD011513. PMID: 27911489 PubMed
Annonse
Annonse